60.39
+0.70
(1.17%)
May 24 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 59.50 - 60.85 |
| 52 week | 37.52 - 60.85 |
| Open | 59.58 |
| Vol / Avg. | 490,474.00/587,644.00 |
| Mkt cap | 3.70B |
| P/E | 49.54 |
| Div/yield | - |
| EPS | 1.22 |
| Shares | 61.30M |
| Beta | 0.65 |
| Inst. own | 98% |
Events
Aug 5, 2013
Q2 2013 Salix Pharmaceuticals Inc Earnings Release
Jun 13, 2013
Salix Pharmaceuticals Inc Annual Shareholder Meeting
- 9:00AM EDT -
May 29, 2013
Salix Pharmaceuticals Inc at 38th Annual dbAccess Health Care Conference
May 14, 2013
Salix Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 9, 2013
Q1 2013 Salix Pharmaceuticals Inc Earnings Conference Call -
May 6, 2013
Q1 2013 Salix Pharmaceuticals Inc Earnings Release
Mar 19, 2013
Salix Pharmaceuticals Inc at Roth Conference
Mar 4, 2013
Salix Pharmaceuticals Inc at Cowen Health Care Conference
Feb 28, 2013
Q4 2012 Salix Pharmaceuticals Inc Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 11.08% | 8.74% |
| Operating margin | 24.32% | 21.28% |
| EBITD margin | - | 38.29% |
| Return on average assets | 4.72% | 4.04% |
| Return on average equity | 15.69% | 11.57% |
| Employees | 525 | - |
| Carbon Disclosure Rating | - | - |
Address
8510 Colonnade Center Drive
RALEIGH, NC 27615
United States - Map
+1-919-8621000 (Phone)
+1-302-5313150 (Fax)
RALEIGH, NC 27615
United States - Map
+1-919-8621000 (Phone)
+1-302-5313150 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�s products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR.
Officers and directors
| Thomas W. D'Alonzo | Independent Chairman of the Board | |
| Carolyn J. Logan | President, Chief Executive Officer, Director | |
| Adam C. Derbyshire | Chief Financial Officer, Executive Vice President - Finance and Administration | |
| William P. Forbes | Executive Vice President - Research and Development, CMO, Chief Development Officer | |
| Rick D. Scruggs | Executive Vice President - Business Development | |
| John F. Chappell | Independent Director | |
| William P Keane | Independent Director | |
| Mark A. Sirgo Pharm.D. | Independent Director |